Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898425271> ?p ?o ?g. }
- W2898425271 abstract "Osteocytes are terminally differentiated cells of the osteoblast lineage. They are involved in the regulation of bone remodeling by increasing osteoclast formation or decreasing bone formation by the secretion of the osteoblast inhibitor sclerostin. Monoclonal antibody anti-sclerostin, Romosozumab, has been developed and tested in clinical trials in patients with osteoporosis. In the last years, the role of osteocytes in the development of osteolytic bone lesions that occurs in multiple myeloma, have been underlined. Myeloma cells increase osteocyte death through the up-regulation of both apoptosis and autophagy that, in turn, triggers osteoclast formation and activity. When compared to healthy controls, myeloma patients with bone disease have higher osteocyte cell death, but the treatment with proteasome inhibitor bortezomib has been shown to maintain osteocyte viability. In preclinical mouse models of multiple myeloma, treatment with blocking anti-sclerostin antibody increased osteoblast numbers and bone formation rate reducing osteolytic bone lesions. Moreover, the combination of anti-sclerostin antibody and the osteoclast inhibitor zoledronic acid increased bone mass and fracture resistance synergistically. However, anti-sclerostin antibody did not affect tumor burden in vivo or the efficacy of anti-myeloma drugs in vitro. Nevertheless, the combination therapy of anti-sclerostin antibody and the proteasome inhibitor carfilzomib, displayed potent anti-myeloma activity as well as positive effects on bone disease in vivo. In conclusion, all these data suggest that osteocytes are involved in myeloma bone disease and may be considered a novel target for the use of antibody-mediated anti-sclerostin therapy also in multiple myeloma patients." @default.
- W2898425271 created "2018-11-02" @default.
- W2898425271 creator A5013923720 @default.
- W2898425271 creator A5046559573 @default.
- W2898425271 creator A5083314734 @default.
- W2898425271 creator A5083766802 @default.
- W2898425271 creator A5086719079 @default.
- W2898425271 date "2018-10-24" @default.
- W2898425271 modified "2023-10-16" @default.
- W2898425271 title "Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic Strategy" @default.
- W2898425271 cites W136099358 @default.
- W2898425271 cites W1495535606 @default.
- W2898425271 cites W1512617915 @default.
- W2898425271 cites W1572248081 @default.
- W2898425271 cites W1582533387 @default.
- W2898425271 cites W1783306815 @default.
- W2898425271 cites W1799961617 @default.
- W2898425271 cites W1808008210 @default.
- W2898425271 cites W1825790816 @default.
- W2898425271 cites W1967063067 @default.
- W2898425271 cites W1970144926 @default.
- W2898425271 cites W1975123703 @default.
- W2898425271 cites W1980486821 @default.
- W2898425271 cites W1982395713 @default.
- W2898425271 cites W1983220846 @default.
- W2898425271 cites W1984890728 @default.
- W2898425271 cites W1985919561 @default.
- W2898425271 cites W1988170766 @default.
- W2898425271 cites W1995417183 @default.
- W2898425271 cites W1997686829 @default.
- W2898425271 cites W1999352200 @default.
- W2898425271 cites W2003754948 @default.
- W2898425271 cites W2005794914 @default.
- W2898425271 cites W2006419043 @default.
- W2898425271 cites W2008314623 @default.
- W2898425271 cites W2011494353 @default.
- W2898425271 cites W2011828467 @default.
- W2898425271 cites W2013070726 @default.
- W2898425271 cites W2013931313 @default.
- W2898425271 cites W2019196925 @default.
- W2898425271 cites W2019582558 @default.
- W2898425271 cites W2026387061 @default.
- W2898425271 cites W2028105165 @default.
- W2898425271 cites W2028910660 @default.
- W2898425271 cites W2029614230 @default.
- W2898425271 cites W2030615058 @default.
- W2898425271 cites W2030816393 @default.
- W2898425271 cites W2031314023 @default.
- W2898425271 cites W2032956576 @default.
- W2898425271 cites W2033776643 @default.
- W2898425271 cites W2035088714 @default.
- W2898425271 cites W2038329170 @default.
- W2898425271 cites W2043500890 @default.
- W2898425271 cites W2043514329 @default.
- W2898425271 cites W2044677383 @default.
- W2898425271 cites W2047882840 @default.
- W2898425271 cites W2051772576 @default.
- W2898425271 cites W2051959338 @default.
- W2898425271 cites W2052498828 @default.
- W2898425271 cites W2053586178 @default.
- W2898425271 cites W2056442040 @default.
- W2898425271 cites W2060336303 @default.
- W2898425271 cites W2062966761 @default.
- W2898425271 cites W2074174622 @default.
- W2898425271 cites W2074494444 @default.
- W2898425271 cites W2075034834 @default.
- W2898425271 cites W2078400068 @default.
- W2898425271 cites W2087560312 @default.
- W2898425271 cites W2096627331 @default.
- W2898425271 cites W2100535572 @default.
- W2898425271 cites W2104490911 @default.
- W2898425271 cites W2106309343 @default.
- W2898425271 cites W2109334521 @default.
- W2898425271 cites W2111471786 @default.
- W2898425271 cites W2112757808 @default.
- W2898425271 cites W2115271834 @default.
- W2898425271 cites W2119962765 @default.
- W2898425271 cites W2122038117 @default.
- W2898425271 cites W2135444604 @default.
- W2898425271 cites W2138023846 @default.
- W2898425271 cites W2138749227 @default.
- W2898425271 cites W2142302926 @default.
- W2898425271 cites W2144207870 @default.
- W2898425271 cites W2153149830 @default.
- W2898425271 cites W2154516862 @default.
- W2898425271 cites W2160088903 @default.
- W2898425271 cites W2167801466 @default.
- W2898425271 cites W2168143492 @default.
- W2898425271 cites W2168587822 @default.
- W2898425271 cites W2183052817 @default.
- W2898425271 cites W2195625763 @default.
- W2898425271 cites W2221806096 @default.
- W2898425271 cites W2261579786 @default.
- W2898425271 cites W2263803297 @default.
- W2898425271 cites W2263881931 @default.
- W2898425271 cites W2292462929 @default.
- W2898425271 cites W2343705381 @default.
- W2898425271 cites W2398309765 @default.
- W2898425271 cites W2520995084 @default.
- W2898425271 cites W2533066994 @default.